MBL-associated serine proteases (MASPs) and infectious diseases.

Journal Information

Full Title: Mol Immunol

Abbreviation: Mol Immunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"chnhdup egf <200 ng/ml cannot bind mbl cannot induce c4 fragment deposition 0 26 @ rs2273344 intron 4 1:g 11045065c>t n a n a. >=600 ng/ml n a 15 rs9430347 intron 5 1:g 11044788t>c n a n a. >=600 ng/ml n a 15 rs17409276 intron 9 1:g 11031148g>a n a n a. >=600 ng/ml n a 15 rs12711521 exon 10 1:g 11030859c>a p d371y ccp2 variable normal 37 rs2273346 exon 10 1:g 11030840a>g p v377a ccp2 <=200 ng/ml normal 9 rs12085877 exon 12 1:g 11027630c>t p r439h sp <=200 ng/ml binds mbl but does not autoactivate cannot activate c4 2 rs1782455 exon 12 1:g 11027467g>a p s493= sp variable n a (synonymous) 29 n a: not applicable cub1: complement c1r/c1s uegf bmp1; ccp: complement control protein; egf: epidermal growth factor; dbsnp: single nucleotide polymorphism database; hgvs: human genome variation society (allele name available in http://www ensembl org ); maf: minor allele frequency; mbl: mannose (or mannan)-binding lectin; @ reference: nm_006610 only in chinese of hong kong ( ) a associated with the minor allele 3 6 masp-2 was characterized by thiel and others in the late 90s as an protein similar to masp-1 ( )."

Code Sharing
COI Disclosure
Evidence found in paper:

"This work was supported by 10.13039/501100003593CNPq – Brazil (Conselho Nacional de Desenvolvimento Científico e Tecnológico) and 10.13039/501100002322CAPES – Brazil (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025